An evaluation of elvitegravir plus cobicistat plus tenofovir alafenamide plus emtricitabine as a single-tablet regimen for the treatment of HIV in children and adolescents
Articolo
Data di Pubblicazione:
2019
Citazione:
An evaluation of elvitegravir plus cobicistat plus tenofovir alafenamide plus emtricitabine as a single-tablet regimen for the treatment of HIV in children and adolescents / V. Giacomet, M.V. Cossu, A.F. Capetti, G.V. Zuccotti, G. Rizzardini. - In: EXPERT OPINION ON PHARMACOTHERAPY. - ISSN 1465-6566. - 20:3(2019 Feb 11), pp. 269-276. [10.1080/14656566.2018.1559299]
Abstract:
Introduction: Approximately 2.1 million of the estimated 36 million infected with HIV are children or adolescents. International guidelines for HIV-1 Infection suggest starting antiretrovirals (ARV) at the moment of diagnosis. Many factors limit the optimization of antiretroviral therapy in children and adolescents: lack of pediatric formulations, poor adherence, metabolic and pharmacokinetic changes associated withnormal child development and puberty. Areas covered: Three integrase inhibitors are approved by the US Food and Drug Administration and by European Medical Agency for children and adolescents with HIV-1 infection. Raltegravir is approved for children aged 4 weeks to 18 years, while dolutegravir and elvitegravir co-formulated with cobicistat, emtricitabine, and tenofovir alafenamide (E/C/FTC/TAF) are approved for children from 6 years of age. This article evaluates E/C/FTC/TAF as a treatment option. Expert opinion: E/C/FTC/TAF was well tolerated, and the antiretroviral activity and tolerability data of this combination support the use in children and adolescents. However, the studies regarding E/C/FTC/TAF in children and adolescents are scant. Consequently, additional studies investigating its safety and efficacy in children are paramount.
Tipologia IRIS:
01 - Articolo su periodico
Keywords:
Elvitegravir; adolescent; antiretroviral therapy; children; cobicistat; Adenine; Adolescent; Anti-HIV Agents; Child; Cobicistat; Emtricitabine; HIV Infections; Humans; Quinolones; Tablets; United States; United States Food and Drug Administration
Elenco autori:
V. Giacomet, M.V. Cossu, A.F. Capetti, G.V. Zuccotti, G. Rizzardini
Link alla scheda completa: